Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DENV-3-LVHC (Dengue Virus-3 Live Virus Human Challenge) is a characterized strain of Dengue virus serotype 3, specifically strain CH53489, utilized in Controlled Human Infection Models (CHIM). Developed and managed by the State University of New York (SUNY) Upstate Medical University, this live virus preparation is used to safely induce a controlled dengue infection in healthy adult volunteers. The primary objective of using DENV-3-LVHC is to study the clinical progression, viral kinetics, and immunologic responses associated with dengue infection and reinfection. These studies provide essential data for the development of dengue vaccines and therapeutics, allowing researchers to evaluate efficacy and the correlates of protection in a controlled clinical environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DENV-3-LVHC-State University of New York - Upstate Medical University.